Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. 2017

Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
aDepartment of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan bCollege of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan cDepartment of Nephrology, Division of Medicine Keelung Chang Gung Memorial Hospital, Keelung, Taiwan dDepartment of General Surgery, Division of Surgery, Keelung Chang Gung Memorial Hospital, Taiwan eDepartment of Oncology and Hematology, Division of Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan fDepartment of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.

BACKGROUND The prognostic relevance of topoisomerase II alpha (TOP2A) copy number change remains not well established. This study is aimed to investigate the frequency and pattern of TOP2A aberrations; to correlate TOP2A alterations with human epidermal growth factor receptor 2 (HER2) status and clinicopathological parameters, and further to explore prognostic value of TOP2A and HER2 status in breast cancer in Taiwan. METHODS We analyzed tissue samples from 311 invasive carcinomas in tissue microarrays for TOP2A and HER2 status by fluorescent in situ hybridization. RESULTS TOP2A copy number change is an infrequent genetic event (9.8% amplification and 2.7% deletion) and is present in both HER2-amplified and nonamplified tumors. TOP2A amplification is statistically associated with age >50 at diagnosis (P = 0.016) and HER2 amplification (P < 0.001). HER2 amplification, but not TOP2A amplification, is a predictor of unfavorable prognosis (P = 0.002). Univariate and multivariate analysis showed that higher histologic grading, positive nodal involvement, and HER2 positivity were associated with poorer overall survival. Cytogenetically, double minutes-type amplification is the predominant pattern for both genes (HER2: 64% and TOP2A: 93.1%). Homogeneous staining region-type signals of both genes are resistant to RNase digestion, supporting that these were not nuclear accumulation of mRNA transcripts. CONCLUSIONS Our results demonstrate the prognostic value of tumor grading, nodal involvement, and HER2 status in Taiwanese breast cancer. TOP2A aberrations are an infrequent event independent of HER2 status, and TOP2A amplification carries no prognostic value. The predictive value of TOP2A aberrations in patients of breast cancer taking athracycline-containing treatment in Taiwan remains to be determined in prospectively well-designed clinical trials.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000075223 Poly-ADP-Ribose Binding Proteins Proteins that contain POLY-ADP RIBOSE BINDING MOTIFS. They include HISTONES and other proteins that function in DNA REPAIR, replication, gene transcription, and APOPTOSIS. pADPr-Binding Proteins,Binding Proteins, Poly-ADP-Ribose,Poly ADP Ribose Binding Proteins,pADPr Binding Proteins

Related Publications

Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
January 2004, Acta oncologica (Stockholm, Sweden),
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
January 2010, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
January 2006, Acta oncologica (Stockholm, Sweden),
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
July 2007, Journal of clinical pathology,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
May 2014, Breast cancer research and treatment,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
May 2015, Diagnostic pathology,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
April 2010, Molecular oncology,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
May 2008, Laboratory investigation; a journal of technical methods and pathology,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
December 2003, Cytopathology : official journal of the British Society for Clinical Cytology,
Jim-Ray Chen, and Hui-Ping Chien, and Kuo-Su Chen, and Cheng-Cheng Hwang, and Huang-Yang Chen, and Kun-Yan Yeh, and Tsan-Yu Hsieh, and Liang-Che Chang, and Yuan-Chun Hsu, and Ren-Jie Lu, and Chung-Ching Hua
February 2012, British journal of cancer,
Copied contents to your clipboard!